Document is current
Any future updates will be listed below
-
Authors
John, Jessy
Al-Hatamleh, Mohammad A. I.
Vashisht, Monika
Shivarudrappa, Arpitha H.
Ge, Huaibin
Siddoway, Karen
Bragoli, Anthony J.
Singh, Priya
Zaky, Mohamed Y.
Zandberg, Dan P.
Zhang, Qiyiwen
Danielsen, Mathias
Ciba, Marija
Lášek, Tomáš
Schafer, Balazs
Caruthers, Marvin H.
Gao, Yuefeng
Liu, Xuedong
Chen, Zhangguo
Wang, Jing H.
-
Funding
Funding for this research was provided by:
National Institute of Dental and Craniofacial Research
- License Information
-
More Information
Article History
Received: 14 October 2025
Accepted: 18 May 2026
First Online: 9 June 2026
Declarations
:
: Animal work was approved by the Institutional Animal Care and Use Committee of University of Pittsburgh (Pittsburgh, PA). Serum samples of de-identified HNSCC patients were provided by UPMC Hillman Cancer Center HNC tissue bank (IRB protocol# HCC 99-069).
: Not applicable.
: DPZ discloses consulting/advisory role for Blueprint medicines, Macrogenics, Prelude therapeutics, Merck, InhibRx, Seagen, BICARA, Coherus. All other authors declare that there is no conflict of interest in relation to the work described.
